Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 25
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic Variants at the 9p21.3 Locus Are Associated with Risk for Non-Compressible Artery Disease, Results from the ARTPER Study

  • Via, Marc|||0000-0002-9966-9921
  • Pera, Guillem|||0000-0003-3188-7268
  • Forés Raurell, Rosa|||0000-0001-7803-7442
  • Costa-Garrido, Anna|||0000-0001-5428-1408
  • Heras, Antonio|||0000-0001-8132-6712
  • Baena Díez, José Miguel
  • Pedrosa, Edurne
  • Clemente, Inmaculada C.
  • Lamonja-Vicente, Noemí|||0000-0003-1342-1130
  • Mataró, M.
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Alzamora, M. Teresa|||0000-0002-0094-6547
Peripheral artery disease (PAD) and non-compressible artery disease (NCAD) constitute predictors of subclinical atherosclerosis easily assessed through the ankle brachial index (ABI). Although both diseases show substantial genetic influences, few genetic association studies have focused on the ABI and PAD, and none have focused on NCAD. To overcome these limitations, we assessed the role of several candidate genes on the ABI, both in its continuous distribution and in the clinical manifestations associated to its extreme values: PAD and NCAD. We examined 13 candidate genomic regions in 1606 participants from the ARTPER study, a prospective population-based cohort, with the ABI assessed through ultrasonography. Association analyses were conducted independently for individuals with PAD (ABI < 0.9) or with NCAD (ABI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metabolic profile of N-ethylhexedrone, N-ethylpentedrone, and 4-chloromethcathinone in urine samples by UHPLC-QTOF-HRMS

  • Massano, Marta
  • Nuñez-Montero, Melani
  • Papaseit, Esther|||0000-0003-2620-4274
  • Hladun, Olga|||0000-0002-6230-5876
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Ventura, Mireia|||0000-0003-1133-6872
  • Marchei, Emilia|||0000-0002-7158-6032
  • Alladio, Eugenio
  • Gerace, Enrico
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Salomone, Alberto
Forensic laboratories are constantly required to identify new drugs and their metabolites. N-ethylhexedrone (NEH, HEXEN), N-Ethylpentedrone (NEP), and 4-Chloromethcathinone (4-CMC, clephedrone) are synthetic substances structurally related to natural cathinone, alkaloid present in the leaves of the Catha edulis (Khat) plant. These synthetic cathinones (SC) are members of the heterogenous family of new psychoactive substances (NPS) that raised major concerns in scientific and forensic communities over the past years due to their widespread consumption. In this context, we investigated their metabolic profile using of UHPLC-QTOF-HRMS to elucidate the distribution of the parent drug and its metabolites in urine samples over time. Initially, both male and female volunteers were divided into three groups and eight subjects of each group were administered intranasally or orally with one SC (20-40 mg of NEH or NEP intranasal, 100-150 mg of 4-CMC oral). Urine samples were collected at 0-2 and 2-4 or 2-5 h. Urine (50 μL) was diluted 1:2 with acetonitrile/methanol (95:5) and injected into the UHPLC-QTOF-HRMS. Phase-I and phase-II metabolites were identified on the basis of fragmentation patterns and exact masses. Several phase-I and glucuronide-phase-II metabolites were identified in urine samples. Keto group reduction, hydroxylation and dealkylation were the common metabolic pathways identified for all cathinones and the presence of NEH-glucuronide, NEP-glucuronide and 4-CMC-glucuronide was also relevant. Significant is the slower metabolite formation for 4-CMC, which was detected at high concentrations in its original form even 5 h after administration, due to its long half-life and low intrinsic clearance compared to the other SCs. UHPLC-QTOF-HRMS demonstrated a considerable capability to semi-quantify the three synthetic cathinones and identify the target metabolites with high reliability. The introduction of new target compounds improves the efficiency of toxicological screening analysis on real samples and extends the window of detection of the SCs in biological matrices.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Mild Presentation of X-Linked Hypophosphatemia Caused by a Non-Canonical Splice Site Variant in the PHEX Gene

  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Herreros García, Alba|||0009-0003-0451-7568
  • Pybus, Marc|||0000-0002-6195-5738
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Furlano, Monica|||0000-0003-1025-3901
  • Garcia Borau, Maria José|||0000-0002-8223-8033
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
X-linked hypophosphatemia (XLH) is a rare inherited disorder of renal phosphate wasting with a highly variable phenotype caused by loss-of-function variants in the PHEX gene. The diagnosis of individuals with mild phenotypes can be challenging and often delayed. Here, we describe a three-generation family with a very mild clinical presentation of XLH. The diagnosis was unexpectedly found in a 39-year-old woman who was referred for genetic testing due to an unclear childhood diagnosis of a tubulopathy. Genetic testing performed by next-generation sequencing using a kidney disease gene panel identified a novel non-canonical splice site variant in the PHEX gene. Segregation analysis detected that the consultand's father, who presented with hypophosphatemia and decreased tubular phosphate reabsorption, and the consultand's son also carried this variant. RNA studies demonstrated that the non-canonical splice site variant partially altered the splicing of the PHEX gene, as both wild-type and aberrant splicing transcripts were detected in the two male members with only one copy of the PHEX gene. In conclusion, this case contributes to the understanding of the relationship between splicing variants and the variable expressivity of XLH disease. The mild phenotype of this family can be explained by the coexistence of PHEX transcripts with aberrant and wild-type splicing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of Tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Bañares-Sánchez, Joan
  • Prio-Ruatg, Alba
  • Martínez-Valle, Ferran
  • Kirkegaard, Cristina|||0000-0001-9035-1450
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Background: The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design: Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels.
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Elevated Plasma GDF-15 Levels are Associated with the Immune Non-Responder Phenotype in People with HIV

  • López López, Aida
  • Alonso Domínguez, Jacobo
  • Martínez Barros, Inés
  • Pérez González, Alexandre
  • Ocampo, Antonio
  • Morano, Luis
  • Martínez López de Castro, Noemí
  • Bisbal Pardo, Otilia
  • Díez, Cristina
  • Arcos-Rueda, Maria del Mar
  • Álvarez-Rodríguez, Ignacio
  • Portilla-Tamarit, Irene
  • Bernal-Morell, Enrique
  • López Cortés, Luis
  • Ruiz-Mateos, Ezequiel
  • Poveda, Eva
  • CoRIS cohort
  • Portilla-Tamarit, Irene|||/items/341962ea-60c0-459e-9454-90e3f9b71000
Introduction: Most people with HIV (PWH) achieve immune recovery with antiretroviral therapy (ART); however, a clinically relevant subset, known as immune non-responders (INRs), fails to restore CD4+ T-cell counts despite sustained virological suppression and shows persistent immune dysfunction. Growth differentiation factor 15 (GDF-15), a stress-responsive cytokine associated with inflammation, aging, chronic disease, and multimorbidity, has not been characterized across distinct HIV viro-immunological phenotypes. Methods: We conducted an exploratory cross-sectional study including 80 PWH classified as ART-naïve individuals, virally suppressed INRs, elite controllers (ECs), and ART-treated immune responders (IRs), as well as 20 HIV-negative controls. Plasma GDF-15 levels were measured by immunoassay. Associations with log-transformed GDF-15 concentrations were assessed using multivariable linear regression including age, CD4+ T-cell nadir, and INR status. Results: INRs showed the highest plasma GDF-15 levels (median, 1143.9 pg/ml), significantly exceeding those observed in ART-naïve individuals, ECs, IRs, and HIV-negative controls (all p ≤ 0.002). GDF-15 levels correlated positively with age, time since HIV diagnosis, and ART duration, and inversely with CD4+ T-cell nadir and the CD4/CD8 ratio (all p ≤ 0.001). In adjusted analysis, INR status remained independently associated with higher log-transformed GDF-15 levels (β = 0.271, 95% CI 0.062–0.480; p = 0.012), corresponding to 31.1% higher GDF-15 concentrations relative to non-INR participants. Conclusion: Plasma GDF-15 levels were higher in virally suppressed INRs than in other viro-immunological groups and remained independently associated with INR status after adjustment for selected covariates. These findings support further investigation of GDF-15 as a potential biomarker of incomplete immune recovery and residual biological stress in virally suppressed PWH. Prospective studies are warranted to validate its clinical and pathophysiological relevance.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The Multispecies Microbial Cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a Precision Biomarker for Colorectal Cancer Diagnosis

  • Ladra, Susana
  • Poza, Margarita
  • Conde-Pérez, Kelly
  • Aja-Macaya, Pablo
  • Buetas, Elena
  • Trigo Tasende, Noelia
  • Nasser-Ali, Mohammed
  • Rumbo-Feal, Soraya
  • Nión, P.
  • Martin-De Arribas, E.
  • Estévez, Lara
  • Otero Alén, Begoña
  • Noguera, José
  • Concha López, Ángel
  • Pardiñas López, Simón
  • Carda-Diéguez, Miguel
  • Gómez-Randulfe, Igor
  • Martínez-Lago, Nieves
  • Antón-Aparicio, Luis M.
  • Bou, Germán
  • Mira, Alex
  • Vallejo, J. A.
[Abstract] The incidence of colorectal cancer (CRC) has increased worldwide, and early diagnosis is crucial to reduce mortality rates. Therefore, new noninvasive biomarkers for CRC are required. Recent studies have revealed an imbalance in the oral and gut microbiomes of patients with CRC, as well as impaired gut vascular barrier function. In the present study, the microbiomes of saliva, crevicular fluid, feces, and non-neoplastic and tumor intestinal tissue samples of 93 CRC patients and 30 healthy individuals without digestive disorders (non-CRC) were analyzed by 16S rRNA metabarcoding procedures. The data revealed that Parvimonas, Fusobacterium, and Bacteroides fragilis were significantly over-represented in stool samples of CRC patients, whereas Faecalibacterium and Blautia were significantly over-abundant in the non-CRC group. Moreover, the tumor samples were enriched in well-known periodontal anaerobes, including Fusobacterium, Parvimonas, Peptostreptococcus, Porphyromonas, and Prevotella. Co-occurrence patterns of these oral microorganisms were observed in the subgingival pocket and in the tumor tissues of CRC patients, where they also correlated with other gut microbes, such as Hungatella. This study provides new evidence that oral pathobionts, normally located in subgingival pockets, can migrate to the colon and probably aggregate with aerobic bacteria, forming synergistic consortia. Furthermore, we suggest that the group composed of Fusobacterium, Parvimonas, Bacteroides, and Faecalibacterium could be used to design an excellent noninvasive fecal test for the early diagnosis of CRC. The combination of these four genera would significantly improve the reliability of a discriminatory test with respect to others that use a single species as a unique CRC biomarker., The authors want to appreciate the good disposition of all the CRC patients for collaborating with us. We would like to thank Gema Carro Díaz and Montserrat Ingelmo Sánchez for their assistance during patients' recruitment time and also during tissue sample collection. This work would not be possible without the support of professionals from the Microbiology, Surgery, Pathology and Oncology Services and Biobank of CHUAC (Spain). The present study received funding from the Instituto de Salud Carlos III (ISCIII), Spain, through the project PI20/00413, cofunded by the European Union (EU) to MP. The whole work has been also supported by the project RTI2018-102032-B-I00 from the Spanish Ministry of Science and Innovation to AM and by CIBER INFEC ISCIII (CB21/13/00055) to GB and MP Biobank of A Coruña was supported by ISCIII-Fondos FEDER (EU) by grant PT20/00128. KC-P was financially supported by the Spanish Association against Cancer (AECC). EB was supported by a grant from the Spanish Ministry of Science and Innovation PRE2019-088126. SL and EM-DA were supported by grants from GAIN (Xunta de Galicia, Spain) with references ED431C 2021/53 and ED431G 2019/01., Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Parvimonas Micra Can Translocate From the Subgingival Sulcus of the Human Oral Cavity to Colorectal Adenocarcinoma

  • Conde-Pérez, Kelly
  • Buetas, Elena
  • Aja-Macaya, Pablo
  • Martin-De Arribas, E.
  • Iglesias Corrás, Iago
  • Trigo Tasende, Noelia
  • Nasser-Ali, Mohammed
  • Estévez, Lara
  • Rumbo-Feal, Soraya
  • Otero Alén, Begoña
  • Noguera, José
  • Concha López, Ángel
  • Pardiñas López, Simón
  • Carda-Diéguez, Miguel
  • Gómez-Randulfe, Igor
  • Martínez-Lago, Nieves
  • Ladra, Susana
  • Antón-Aparicio, Luis M.
  • Bou, Germán
  • Mira, Alex
  • Vallejo, J. A.
  • Poza, Margarita
[Abstract] Oral and intestinal samples from a cohort of 93 colorectal cancer (CRC) patients and 30 healthy controls (non-CRC) were collected for microbiome analysis. Saliva (28 non-CRC and 94 CRC), feces (30 non-CRC and 97 CRC), subgingival fluid (20 CRC), and tumor tissue samples (20 CRC) were used for 16S metabarcoding and/or RNA sequencing (RNAseq) approaches. A differential analysis of the abundance, performed with the ANCOM-BC package, adjusting the P-values by the Holm-Bonferroni method, revealed that Parvimonas was significantly over-represented in feces from CRC patients (P-value < 0.001) compared to healthy controls. A total of 11 Parvimonas micra isolates were obtained from the oral cavity and adenocarcinoma of CRC patients. Genome analysis identified a pair of isolates from the same patient that shared 99.2% identity, demonstrating that P. micra can translocate from the subgingival cavity to the gut. The data suggest that P. micra could migrate in a synergistic consortium with other periodontal bacteria. Metatranscriptomics confirmed that oral bacteria were more active in tumor than in non-neoplastic tissues. We suggest that P. micra could be considered as a CRC biomarker detected in non-invasive samples such as feces., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI20/00413 and co-funded by the European Union to MP. The work has been also supported by the project RTI2018-102032-B-I00 from the Spanish Ministry of Science and Innovation to AM and by the CIBER INF ISCIII (CB21/13/00055) to GB and MP. Biobank of University Hospital Complex of A Coruña was supported by Instituto de Salud Carlos III – Fondos FEDER (EU) by grant PT20/00128. K. Conde-Pérez was financially supported with a predoctoral fellowship by the Asociación Española Contra el Cáncer (AECC). E. Buetas is supported by a grant from the Spanish Ministry of Science and Innovation with the reference PRE2019-088126. S. Ladra, E. Martin-De Arribas and Iago Iglesias-Corrás are supported by grants from GAIN (Xunta de Galicia, Spain) with references ED431C 2021/53 and ED431G, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Privacy-preserving federated machine learning on FAIR health data: A real-world application

  • Sinaci, A. Anil
  • Gencturk, Mert
  • Álvarez-Romero, Celia
  • Laleci Erturkmen, Gokce Banu
  • Martínez-García, Alicia
  • Escalona-Cuaresma, María José
  • Parra-Calderón, Carlos Luis
© 2024 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Objective] This paper introduces a privacy-preserving federated machine learning (ML) architecture built upon Findable, Accessible, Interoperable, and Reusable (FAIR) health data. It aims to devise an architecture for executing classification algorithms in a federated manner, enabling collaborative model-building among health data owners without sharing their datasets., [Materials and methods] Utilizing an agent-based architecture, a privacy-preserving federated ML algorithm was developed to create a global predictive model from various local models. This involved formally defining the algorithm in two steps: data preparation and federated model training on FAIR health data and constructing the architecture with multiple components facilitating algorithm execution. The solution was validated by five healthcare organizations using their specific health datasets., [Results] Five organizations transformed their datasets into Health Level 7 Fast Healthcare Interoperability Resources via a common FAIRification workflow and software set, thereby generating FAIR datasets. Each organization deployed a Federated ML Agent within its secure network, connected to a cloud-based Federated ML Manager. System testing was conducted on a use case aiming to predict 30-day readmission risk for chronic obstructive pulmonary disease patients and the federated model achieved an accuracy rate of 87%., [Discussion] The paper demonstrated a practical application of privacy-preserving federated ML among five distinct healthcare entities, highlighting the value of FAIR health data in machine learning when utilized in a federated manner that ensures privacy protection without sharing data., [Conclusion] This solution effectively leverages FAIR datasets from multiple healthcare organizations for federated ML while safeguarding sensitive health datasets, meeting legislative privacy and security requirements., This work was supported by the FAIR4Health project [35], which received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 824666. Additionally, this study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PT20/00088 and IMP/00019 and co-funded by the European Union., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Detection of SARS-CoV-2 Virus by Triplex Enhanced Nucleic Acid Detection Assay (TENADA)

  • Aviñó, Anna
  • Cuestas-Ayllón, Carlos
  • Gutiérrez-Capitán, Manuel
  • Vilaplana, Lluisa
  • Grazu, Valeria
  • Noé, Véronique
  • Balada, Eva
  • Baldi, Antonio
  • Félix, Alex J.
  • Aubets, Eva
  • Valiuska, Simonas
  • Domínguez, Arnau
  • Gargallo, Raimundo
  • Eritja, Ramon
  • Marco, M.-Pilar
  • Fernández-Sánchez, César
  • Martínez de la Fuente, Jesús
  • Ciudad, Carlos J.
SARS-CoV-2, a positive-strand RNA virus has caused devastating effects. The standard method for COVID diagnosis is based on polymerase chain reaction (PCR). The method needs expensive reagents and equipment and well-trained personnel and takes a few hours to be completed. The search for faster solutions has led to the development of immunological assays based on antibodies that recognize the viral proteins that are faster and do not require any special equipment. Here, we explore an innovative analytical approach based on the sandwich oligonucleotide hybridization which can be adapted to several biosensing devices including thermal lateral flow and electrochemical devices, as well as fluorescent microarrays. Polypurine reverse-Hoogsteen hairpins (PPRHs) oligonucleotides that form high-affinity triplexes with the polypyrimidine target sequences are used for the efficient capture of the viral genome. Then, a second labeled oligonucleotide is used to detect the formation of a trimolecular complex in a similar way to antigen tests. The reached limit of detection is around 0.01 nM (a few femtomoles) without the use of any amplification steps. The triplex enhanced nucleic acid detection assay (TENADA) can be readily adapted for the detection of any pathogen requiring only the knowledge of the pathogen genome sequence.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Associations between eating speed, diet quality, adiposity, and cardiometabolic risk factors

  • Garcidueñas-Fimbres, T. E.
  • Paz-Graniel, I.
  • Gómez-Martínez, C.
  • Jurado-Castro, J. M.
  • Leis, R.
  • Escribano, J.
  • Moreno, L. A.
  • Navas-Carretero, S.
  • Portoles, O.
  • Pérez-Vega, K. A.
  • Gil-Campos, M.
  • López-Rubio, A.
  • Rey-Reñones, C.
  • Miguel Etayo, P. de
  • Martínez, J. A.
  • Flores-Rojas, K.
  • Vázquez-Cobela, R.
  • Luque, V.
  • Miguel Berges, M. L.
  • Pastor-Villaescusa, B.
  • Llorente-Cantarero, F. J.
  • Salas-Salvadó, J.
  • Babio, N.
  • Schröder, H.
  • Moreira, A.
  • Fitó, M.
  • Pérez-Vega, K. A.
  • Solís Baltodano, M.
  • Muñoz-Aguayo, D.
  • Blanchart, G.
  • Gaixas, S.
  • Zomeño, M. D.
  • Lorenzo, I.
  • Gil-Campos, M.
  • Jurado-Castro, J. M.
  • Flores-Rojas, K.
  • Pastor-Villaescusa, B.
  • Llorente-Cantarero, F. J.
  • La Torre-Aguilar, M. J.
  • Velasco Aguayo, I.
  • Navas-Carretero, S.
  • Alfredo-Martínez, J.
  • Cuevillas, B.
  • Goñi, M.
  • Hernández, M.
  • Pérez Diez, S.
  • Cristobo, C.
  • Babio, N.
  • Salas-Salvadó, J.
  • Escribano, J.
  • Luque, V.
  • Ferré, N.
  • Martín, F.
  • Rey, C.
  • Mimbreros, G.
  • Pedraza, A.
  • Salvadó, O.
  • Ruiz Velasco, M.
  • Bilbao Sustacha, J. Á.
  • Herranz Pinilla, Y.
  • Feliu, A.
  • Closas, R.
  • Rios, L.
  • Pascual Compte, M.
  • Gheorghita, I.
  • Gómez-Martínez, C.
  • Heras-Delgado, S. de las
  • Alcázar, M.
  • Simón, O.
  • Torre, S. de la
  • Tudela, C
Objective: To assess the associations between eating speed, adiposity, cardiometabolic risk factors, and diet quality in a cohort of Spanish preschool-children. Study design: A cross-sectional study in 1371 preschool age children (49% girls; mean age, 4.8 ± 1.0 years) from the Childhood Obesity Risk Assessment Longitudinal Study (CORALS) cohort was conducted. After exclusions, 956 participants were included in the analyses. The eating speed was estimated by summing the total minutes used in each of the 3 main meals and then categorized into slow, moderate, or fast. Multiple linear and logistic regression models were fitted to assess the β-coefficient, or OR and 95% CI, between eating speed and body mass index, waist circumference, fat mass index (FMI), blood pressure, fasting plasma glucose, and lipid profile. Results: Compared with participants in the slow-eating category, those in the fast-eating category had a higher prevalence risk of overweight/obesity (OR, 2.9; 95% CI, 1.8-4.4; P < .01); larger waist circumference (β, 2.6 cm; 95% CI, 1.5-3.8 cm); and greater FMI (β, 0.3 kg/m2; 95% CI, 0.1-0.5 kg/m2), systolic blood pressure (β, 2.8 mmHg; 95% CI, 0.6-4.9 mmHg), and fasting plasma glucose levels (β, 2.7 mg/dL, 95% CI, 1.2-4.2 mg/dL) but lower adherence to the Mediterranean diet (β, −0.5 points; 95% CI, −0.9 to −0.1 points). Conclusions: Eating fast is associated with higher adiposity, certain cardiometabolic risk factors, and lower adherence to a Mediterranean diet. Further long-term and interventional studies are warranted to confirm these associations.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Clinical performance evaluation of a rapid real-time PCR assay for monkeypox diagnosis: a retrospective and comparative study

  • Peris, María Paz
  • Clusa, Laura
  • Alonso, Henar
  • Escolar, Cristina
  • Fortuño, Blanca
  • Rezusta, Antonio
  • Milagro, Ana
In an increasingly globalized and interconnected world, the outbreak of an infectious disease in one country can become a worrying health emergency for the whole world. A current example is the 2022 monkeypox virus (mpox) outbreak affecting multiple areas across the world. In this context, strategies to interrupt transmission as soon as possible by identifying cases, clusters, and sources of infection should be developed around the world to prevent these crises. The aim of this retrospective and collaborative study was to perform external clinical validation of the VIASURE monkeypox virus real-time PCR detection kit (CerTest Biotec, Spain) with ready-to-use reagents designed for the rapid detection of mpox. A total of 165 samples with suspected infection were used for this analysis. The standard procedures of the clinical microbiology laboratory of the Miguel Servet University Hospital, using the RealStar Orthopoxvirus PCR kit v1.0 (Altona Diagnostics) and bidirectional Sanger sequencing (STAB VIDA, Caparica, Portugal), were considered reference techniques. Furthermore, a subset of 67 mpox-negative samples and 13 mpox-positive samples were routinely tested for clinical diagnosis of other rash/ulcerative pathologies. Accuracy testing resulted in appropriate clinical validation values, as follows: sensitivity, 1 (95% confidence interval [CI], 0.97 to 1); specificity, 1 (95% CI, 0.98 to 1); positive predictive value, 1 (95% CI, 0.93 to 1); negative predictive value, 1 (95% CI, 0.95 to 1). The strength of agreement between assays was almost perfect. The added value is the useful support for the specific diagnosis of mpox infections due to the diagnostic specificity data obtained.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Novel protocol for the transcriptomic analysis of endothelial extracellular vesicles in atherosclerosis

  • Saenz-Pipaon, Goren
  • Cenarro, Ana
  • Zazpe, Jon
  • Goñi-Oloriz, Miriam
  • Martinez-Aguilar, Esther
  • Machado, Florencio J.D.
  • Marchese, Francesco P.
  • Orbe, Josune
  • López-Andrés, Natalia
  • Civeira, Fernando
  • Paramo, Jose A.
  • Lara-Astiaso, David
  • Roncal, Carmen
Introduction: Despite the key role of the endothelium in atherosclerosis, there are no direct techniques for its analysis. The study of extracellular vesicles of endothelial origin (EEVs), might lead to the identification of molecular signatures and early biomarkers of atherosclerosis. The aim of this work was to set up the methods for EEVs separation and transcriptomic analysis. Methods: We adapted an antibody-magnetic-bead based immunocapture protocol for plasma EEVs separation from control (G1), subclinical atherosclerosis (G2) and peripheral artery disease subjects (PAD) (G3), and modified an ultra-low input RNASeq method (n = 5/group). By bioinformatics analysis we compared the transcriptome of plasma EEVs with that of human aortic endothelial cells (TeloHAECs), and then, searched for differentially expressed genes (DEG) among EEVs of G1, G2 and G3. From those DEG, UCP2 was selected for further validation in plasma EVs (qPCR), and in vitro, in stimulated TeloHAECs (IL-1β, TNFα, oxLDL and hypoxia). Results: The RNASeq analysis of plasma EEVs rendered 1667 genes enriched in transcripts expressed by TeloHAECs (NES: 1.93, p adjust = 1.4e−73). One hundred seventy DEGs were identified between G2 vs G1, and 180 between G3 vs G1, of which 17 were similarly expressed in G2 and G3 vs control, including UCP2. IL-1β and TNFα (10 ng/mL, p < 0.05), hypoxia (1% O2, p = 0.05) and oxLDL (100 μg/mL, p = 0.055) reduced UCP2 expression in TeloHAECs. Conclusions: We set up a protocol for EEVs separation and sequencing that might be useful for the identification of early markers of endothelial dysfunction in atherosclerosis. Introducción: A pesar del papel clave del endotelio en la aterosclerosis, no existen técnicas directas para su análisis. El estudio de las vesículas extracelulares de origen endotelial (EEV) podría facilitar la identificación de firmas moleculares y biomarcadores tempranos de aterosclerosis. El objetivo de este trabajo fue establecer los métodos para la separación de EEV y su análisis transcriptómico. Métodos: Adaptamos un protocolo de inmunocaptura con anticuerpos y microesferas magnéticas para la separación de las EEV del plasma de sujetos control (G1), con aterosclerosis subclínica (G2) y con enfermedad arterial periférica (G3), y modificamos un método de RNASeq para su análisis transcriptómico (n = 5/grupo). Comparamos el transcriptoma de las EEV plasmáticas con el de células endoteliales de aorta humana (TeloHAEC) e identificamos genes diferencialmente expresados (DEG) entre los grupos de pacientes, incluyendo UCP2, validado en EV plasmáticas (qPCR) e in vitro, en TeloHAECs tratadas con IL-1β, TNF-α, oxLDL e hipoxia. Resultados: El RNASeq de las EEV plasmáticas detectó 1.667 genes enriquecidos en transcritos expresados por las TeloHAECs (NES: 1,93, ajuste p = 1,4e−73). Se identificaron 170 DEG entre los grupos G2 vs. G1 y 180 entre G3 vs. G1, de los cuales 17 se expresaron de forma similar en G2 y G3 vs. control, incluyendo UCP2. El tratamiento con IL-1β y TNF-α (10 ng/ml, p < 0,05), hipoxia (1% O2, p = 0,05) y oxLDL (100 μg/ml, p = 0,055) redujo la expresión de UCP2 en las TeloHAEC. Conclusiones: Hemos puesto a punto un protocolo para la separación y la secuenciación de EEV que podría ser útil para la identificación de marcadores tempranos de disfunción endotelial en aterosclerosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers

  • Oliván-Blázquez, Bárbara
  • Bona-Otal, Marta
  • Méndez-López, Fátima
  • Lerma-Irureta, David
  • García-Izuel, Paula
  • Ibáñez-Ruiz, Jesús
  • Montolío, Alberto
  • Ruiz-Herreros, María
  • Godino, Javier
  • Jimeno-Beltran, Beatriz
  • Encabo-Berzosa, María del Mar
  • Arenaz, Izaskun
  • Medel-Martínez, Ana
  • Casado-Vicente, Verónica
  • Coiras, Mayte
  • Tellería-Orriols, Carlos
  • Schoorlemmer, Jon
  • Magallón-Botaya, Rosa
Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19. This study compared biomarkers between two age- and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12–24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels. PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10). A panel of αGAD, IL-10, potassium levels, and CD16brightCD56− cell presence distinguished PCC individuals from recovered patients with >88% accuracy and <92% precision.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Combination of exhaled volatile organic compounds with serum biomarkers predicts respiratory infection severity

  • Esteban, Patricia
  • Letona-Gimenez, Santiago
  • Domingo, Maria Pilar
  • Morte, Elena
  • Pellejero-Sagastizabal, Galadriel
  • Encabo, Maria del Mar
  • Ramírez-Labrada, Ariel
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño, José Ramón
  • Galvez, Eva M.
Objective. During respiratory infections, host-pathogen interaction alters metabolism, leading to changes in the composition of expired volatile organic compounds (VOCs) and soluble immunomodulators. This study aims to identify VOC and blood biomarker signatures to develop machine learning-based prognostic models capable of distinguishing infections with similar symptoms. Methods. Twenty-one VOCs and fifteen serum biomarkers were quantified in samples from 86 COVID-19 patients, 75 patients with non-COVID-19 respiratory infections, and 72 healthy donors. The populations were categorized into severity subgroups based on their oxygen support requirements. Descriptive and statistical analyses were conducted to assess group differentiation. Additionally, machine learning classifiers were developed to predict disease severity in both COVID-19 and non-COVID-19 patients. Results. VOC and biomarker profiles differed significantly among groups. Random Forest models demonstrated the best performance for severity prediction. The COVID-19 model achieved 93% accuracy, 100% sensitivity, and 89% specificity, identifying IL-6, IL-8, thrombomodulin, and toluene as key severity predictors. In non-COVID-19 patients, the model reached 89% accuracy, 100% sensitivity, and 67% specificity, with CXCL10 and methyl-isobutyl-ketone as key markers. Conclusion.VOCs and serum biomarkers differentiated HD, COVID-19, and non-COVID-19 patients, and enabled the development of high-performance severity prediction models. While promising, these findings require validation in larger independent cohorts.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Expression Profiles of Exosomal miRNAs in Gaucher Patients and Their Association With Severity of Bone Involvement

  • Serrano-Gonzalo, Irene
  • López de Frutos, Laura
  • Sancho-Albero, Maria
  • Roca-Espiau, Mercedes
  • Köhler, Ralf
  • Giraldo, Pilar
Bone manifestations are one of the most prevalent complications in patients with Gaucher disease (GD). Bone involvement is evaluated by using imaging methods, and there are different scores to assess its severity. However, there are no biomarkers that allow us to predict these manifestations. In recent years, several miRNAs have been associated with bone involvement and postulated as excellent bioavailable biomarkers. This study aims to identify a miRNA expression profile from plasma exosomes and to associate it with the severity of bone involvement in patients with GD. This study included 60 untreated patients with GD with bone involvement, who were classified according to the S‐MRI score into three groups: mild disease (MiBD; S‐MRI < 5), moderate disease (MoBD; S‐MRI: 5–11), or severe disease (SBD; S‐MRI > 11). Plasma exosomes were purified, and miRNAs were extracted and identified by next‐generation sequencing (NGS) technology. Differentially expressed miRNAs were validated by droplet digital PCR (ddPCR). In the patients' groups classified by S‐MRI, the median ages (Q1–Q3) were: MiBD 19.0 (4.00–40.00), MoBD 40.5 (28.25–56.00), and SBD 37.5 (31.25–47.00) years. When comparing groups, we found 12 differentially expressed exosomal miRNAs. After validation, four miRNAs were identified as differentially expressed: hsa‐miR‐127‐3p, hsa‐miR‐184, hsa‐miR‐197‐3p, and hsa‐miR‐660‐5p. Notably, hsa‐miR‐127‐3p, hsa‐miR‐660‐5p, and hsa‐miR‐184 were correlated with the presence of infarcts, necrosis, and the degree of infiltration into the spine, pelvis, and femur. These three miRNAs could serve as bioavailable biomarkers to assess bone disease in GD, and further revalidation with a higher number of patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Region-Specific Expression Patterns of lncRNAs in the Central Nervous System: Cross-Species Comparison and Functional Insights

  • López-Royo, Tresa
  • Gascón, Elisa
  • Moreno-Martínez, Laura
  • Macías-Redondo, Sofía
  • Zaragoza, Pilar
  • Manzano, Raquel
  • Osta, Rosario
Increasing evidence demonstrates that long noncoding RNAs (lncRNAs) are crucial for brain evolution and proper development and function of the central nervous system (CNS), exhibiting specific time-, spatial-, and sex-biassed expression patterns. This study investigated whether region-specific spatial expression patterns of brain-relevant lncRNAs are conserved between the mouse and human CNS. Demonstrating such cross-species conservation informs the translational value of mouse models for lncRNA biology. To test this, the expression of 14 lncRNAs was studied in the adult CNS of mice and humans across three different regions (spinal cord, brainstem, and frontal cortex), and age effects were assessed in mice. The results demonstrated conserved expression patterns between the two species, with region-specific changes. The frontal cortex exhibited high expression of Meg3, Miat, and Pvt1 lncRNAs, while the spinal cord showed high levels of Hotair and Gas5. Additionally, Malat1 displayed lower levels in females compared to males in the spinal cord compared to other regions. Finally, through GO functional enrichment analysis and literature review, this study emphasizes the role of lncRNAs in CNS physiology and disease, suggesting their involvement in neurological processes and conditions such as cortical development, neuronal synapsis, schizophrenia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis. Overall, this research highlights the importance of further investigating the role of lncRNAs in brain function and their potential as key players in neurological disorders, opening the door to explaining the high region- and sex-specific effects of these disorders.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Antimicrobial therapy among hospitalized older adults with suspected infection and negative blood cultures

  • Pellejero-Sagastizabal, Galadriel
  • Morte-Romea, Elena
  • Girón Ortega, José Antonio
  • Paño-Pardo, José Ramón
  • Fernández Guerrero, Raquel
  • Guerrero, Francisca
  • Montes de Oca, Montserrat
  • Jiménez-Jorge, Silvia
  • Palacios-Baena, Zaira R.
  • Rodríguez-Baño, Jesús
  • Retamar-Gentil, Pilar
  • Montes de Oca Arjona, Montserrat
  • Galán Sánchez, Fátima
  • Rodríguez Mateos, María Eugenia
  • Girón-González, José Antonio
  • Martín Aspas, Andrés
  • Sánchez Tembleque, Claudio
  • Guerrero Sánchez, Francisca María
  • Morte-Romea, Elena
  • Pellejero-Sagastizabal, Galadriel
  • Luque Gómez, Pilar
  • Paño-Pardo, José Ramón
  • Sierra, José Luis
  • Letona Gimenez, Santiago
  • Palacián, Pilar
  • Rodriguez, Nora Mariela
  • Arenere Mendoza, Mercedes
  • Allende Bandrés, Maria Ángeles
  • Fresquet Molina, Raquel
  • Navarro Pardo, Irene
  • Girón Ortega, José Antonio
  • Fernández Guerero, Raquel
  • Retamar-Gentil, Pilar
  • Palacios-Baena, Zaira
  • de Cueto, Marina
  • Beltrán García, Margarita
  • Cantón Bulnes, María Luisa
  • Suarti, Lorenzo Roberto
  • Rodríguez-Baño, Jesús
Background Managing infections in older adults is challenging due to their unique characteristics, which often drives empirical antimicrobial use, increasing risks of adverse outcomes and antimicrobial resistance (AMR). Data on antimicrobial adequacy in older patients with suspected infection but negative blood cultures (BC) remain scarce, despite this being a common clinical scenario. Methods In this multicenter prospective cohort study (NO-BACT project) across three Spanish hospitals (2018–2019), we compared antimicrobial therapy adequacy between older adults (≥ 85 years) and younger patients with suspected infections and negative BC. Antimicrobial stewardship (AMS) experts evaluated treatment adequacy at days 2 and 5–7 using standardized guideline-based criteria. We assessed predictors of adequacy using logistic regression and examined clinical outcomes including 30-day mortality and length of hospital stay (LOS). Results Among 799 enrolled patients, 90 (11.3%) were older adults. While initial antimicrobial adequacy was comparable between groups at Day 2 (59.8% vs. 60.1%), older adults were significantly less likely to receive adequate treatment by Days 5–7 (adjusted OR 0.46, 95% CI 0.25–0.82, p = 0.009). The main drivers of inadequacy were excess antimicrobial spectrum (84.2%) and inappropriate route of administration (48.7%). Older adults demonstrated higher 30-day mortality (16.7% vs. 7.8%; p = 0.009) despite shorter LOS (8 vs. 10 days, p = 0.006), though treatment adequacy was not associated with mortality. Conclusions In older patients with negative BC, antimicrobial therapy shows high rates of inadequacy that worsen over time, primarily due to delayed de-escalation and prolonged intravenous therapy. These findings identify a clear target for AMS interventions focusing on timely treatment optimization.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Metabolomic profiling of ultra-processed food consumption and cardiovascular risk in Spanish preschool children: a cross-sectional study

  • Pérez-Acosta, Josué A.
  • García-Gavilán, Jesús F.
  • Margara-Escudero, Hernando J.
  • Aguilera, Concepción M.
  • Leis, Rosaura
  • Gheorghita, Irina
  • Miguel-Berges, María L.
  • Navas-Carretero, Santiago
  • Sorlí, José V.
  • Lázaro, Iolanda
  • Pastor-Villaescusa, Belén
  • Vázquez-Cobela, Rocío
  • Iglesias-Vázquez, Lucía
  • De Miguel-Etayo, Pilar
  • Vazquez-Bolea, Natalia
  • Jurado-Castro, José Manuel
  • Picáns-Leis, Rosaura
  • Escribano, Joaquín
  • Moreno, Luis A.
  • Torre-Aguilar, MJosé de la
  • Gil-Campos, Mercedes
  • Salas-Salvadó, Jordi
  • Babio, Nancy
Background Ultra-processed food (UPF) consumption has increased substantially among children worldwide and has been associated with early cardiovascular alterations. We aimed to identify plasma metabolomic profiles associated with UPF consumption in children aged 3–6 years and to assess their association with cardiovascular risk factors. Methods This cross-sectional analysis used baseline data from the Childhood Obesity Risk Assessment Longitudinal Study (CORALS), with children recruited between March 2019 and June 2022 through primary schools and health-care centres in seven Spanish cities. 1148 children were included (mean age 5.0 years [SD 1.1]; 50.6% girls) after exclusions due to medical conditions and incomplete or implausible dietary or metabolomic data. Energy-adjusted UPF intake (g/d) was assessed using a validated food frequency questionnaire and categorised with NOVA classification. 249 metabolites were quantified by NMR-based metabolomics, and lipid-related and amino acid-related profiles/scores were derived. A composite cardiovascular risk score (CVRs) was constructed by summing sex-specific, age-adjusted z-scores for fat-mass index, HDL-and LDL-cholesterol, triglycerides, mean arterial pressure, and Homoeostatic Model Assessment for Insulin Resistance. Findings 19 metabolites were associated with UPF consumption after false discovery rate correction (FDR). A lipid-related score was positively associated with CVRs (β = 0.511; 95% CI: 0.413–0.610; FDR <0.001) and the amino acid–related score was associated with a lower CVRs (β = −0.494; 95% CI: −0.667 to −0.321; FDR <0.001). Discrimination of cardiovascular risk beyond covariates alone was higher after inclusion of metabolomic scores, particularly when both scores were considered jointly (ΔAUC 0.092, 95% CI: 0.013–0.172; p = 0.020). Interpretation In Spanish pre-schoolers UPF-related metabolomic profiles were associated with different cardiovascular risk factors. These diet-related metabolomic scores capture biological correlates relevant to early cardiovascular health and align with early-life metabolic pattering, supporting future longitudinal studies and prevention strategies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Augustin Recio, Salvador
  • Prió, Alba
  • Sellarès-Nadal, Júlia
  • Espinosa-Pereiro, Juan
  • Burgos, Joaquin
  • Falcó, Vicenç
  • Guillen-Del-Castillo, Alfredo
  • Bañares, Juan
  • Martínez-Valle, Fernando
  • Kirkegaard, Cristina
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Acute respiratory distress syndrome; COVID-19; Interleukin-6, Síndrome de dificultat respiratòria aguda; COVID-19; Interleucina-6, Síndrome de dificultad respiratoria aguda; COVID-19; Interleucina-6, Background The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels > 40 pg/mL. Methods Patients were randomized 1:1 to receive standard of care (SOC) or SOC plus one dose of tocilizumab. The primary outcome was death or need for invasive mechanical ventilation (IMV) within 28 days after randomization. Secondary outcomes included ICU admission, days on IMV and hospital stay. A meta-analysis of clinical trials to evaluate the effect of tocilizumab on mortality and need of IMV in patients with COVID-19 pneumonia was performed. Results Sixty-two patients were included: 30 in the SOC arm and 32 in the standard-treatment plus tocilizumab arm. The primary outcome occurred in 12.9% in the tocilizumab arm and 32.3% in the SOC arm(p = 0.068). There was a trend towards fewer days on IMV (7.5 vs 19.5 days, p = 0.073) and a shorter hospital stay (4 vs 8 days, p = 0.134) in the tocilizumab group. No serious adverse events were reported. The meta-analysis revealed a RR for death or IMV of 0.83 (95% CI: 0.77–0.89) in patients receiving tocilizumab, compared to patients receiving SOC. Conclusion Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19., Open Access Funding provided by Universitat Autonoma de Barcelona. This study received support of “Plataforma ISCIII de Soporte para la Investigación Clínica—SCReN (Spanish Clinical Research Network)” which is funded by ISCIII through the project sPT17/0017/0030 and PT20/00078, which are both integrated in the “Plan Estatal de I + D + I 2013–2016 y 2017–2020” and co-funded by the “ Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa””. ASM was supported by the Instituto de Salud Carlos III (Juan Rodés postdoctoral fellowship grant number JR18/00022) during the study period. JSN and JEP are supported by the Instituto de Salud Carlos III (Rio Hortega predoctoral grant numbers CM22/00262 and CM22/00246).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Effect of Probiotics on Preterm Birth Rates in Pregnant Women After a Threatened Preterm Birth Episode (The PROPEV Trial)

  • Miserachs Sala, Marta
  • Puerto Tamayo , Linda Grace
  • Garrido-Giménez, Carmen
  • Soler, Zaida
  • Dalmau Artal, Marta
  • Casellas de Miguel, Alba
  • Carreras, Elena
  • Goya, Maria
  • del Barco Martínez, Ester
  • González Molano, Leidy Alejandra
  • VARGAS BUJÁN, MIREIA
  • Chaysavanh, Manichanh
Microbiota; Preterm birth; Probiotics, Microbiota; Parto prematuro; Probióticos, Microbiota; Part prematur; Probiòtics, Introduction: Preterm birth is the leading cause of perinatal mortality worldwide, with prevalence rates showing little reduction. Although mortality rates have decreased, morbidity rates remain concerningly high. In recent years, there has been a surge in studies examining the etiology, risk factors, and management of preterm birth. The use of vaginal probiotics in pregnant women at risk of preterm birth has garnered attention as a potential approach for improving perinatal outcomes and modulating the vaginal microbiota. However, the efficacy of this intervention remains unclear. Therefore, this study explored the impact of vaginal probiotics on perinatal outcomes and vaginal microbiota composition in pregnant women at risk of preterm birth. Materials and Methods: This was a randomized, prospective, longitudinal, double-blind, placebo-controlled, multicentric trial conducted across seven maternities in Spain from October 2017 to August 2022 in pregnant women at risk of preterm birth. Participants were randomly assigned to receive vaginal probiotics containing four lactobacilli strains or a placebo. The primary outcome was to explore a potential correlation between probiotic use among pregnant women at risk of preterm birth and the actual rate of preterm birth before 37 gestational weeks. Secondary outcomes included an evaluation of preterm birth rates, neonatal morbidity, the vaginal microbiota, and changes in the vaginal microbiota after receiving probiotics. Other secondary outcomes were identifying vaginal microbiota patterns associated with preterm birth and exploring potential therapeutic mechanisms involving probiotics. Trial registration: Clinicaltrials.gov, identifier: NCT03689166. Results: A total of 200 participants were included. Of those, birth data were obtained for 181 women. Demographics were similar between both groups. An analysis of perinatal outcomes found no significant differences in preterm birth rates, prematurity rates, gestational weeks at delivery, neonatal complications, time to birth, or latency time to delivery. Microbiota analysis showed no significant differences in vaginal microbiota changes between groups. No serious or unexpected adverse reactions were reported. Conclusions: There were no statistically significant differences for spontaneous preterm birth between pregnant women receiving probiotics and pregnant women receiving the placebo., This work was supported by the Spanish Clinical Research Network (SCReN), which is funded by the ISCIII-General Subdirectorate for Evaluation and Promotion of Research through projects PT17/0017/0030 and PT20/00078. Both projects were integrated into the 2013–2016 National Plan for Scientific and Technical Research and Innovation and co-financed by the European Regional Development Fund (ERDF), “A way of making Europe”. This work was also supported by Project FIS PI 19/00287 (Maria Goya as a principal investigator), which was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. Laboratorios Ordesa S.L funded the PROPEV study. L.-A.G.M. was supported by Instituto de Salud Carlos III/FEDER (PI20/00130).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Cristóbal, Helena
  • Iglesias, Mar|||0000-0002-2274-4671
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Barranco, Luis E
  • Visa, Laura|||0000-0002-3409-8857
  • Calafato, Domenico|||0000-0002-9636-9819
  • Jiménez-Parrado, Silvia
  • Earl, Julie
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Manero-Rupérez, Noemí
  • Moreno Merino, Mireia|||0000-0001-9575-5112
  • Morales, Albert|||0000-0001-8702-2269
  • Guerra, Carmen
  • Navarro, Pilar|||0000-0003-4314-4584
  • García de Frutos, Pablo|||0000-0003-1547-1190
Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. Here we explore the use of sAXL as a biomarker for PDAC. AXL was analysed by immunohistochemistry in human pancreatic tissue samples. RNA expression analysis was performed using TCGA/GTEx databases. The plasma concentrations of sAXL, its ligand GAS6, and CA19-9 were studied in two independent cohorts, the HMar cohort (n = 59) and the HClinic cohort (n = 142), including healthy controls, chronic pancreatitis (CP) or PDAC patients, and in a familial PDAC cohort (n = 68). AXL expression and sAXL release were studied in PDAC cell lines and murine models. AXL is increased in PDAC and precursor lesions as compared to CP or controls. sAXL determined in plasma from two independent cohorts was significantly increased in the PDAC group as compared to healthy controls or CP patients. Patients with high levels of AXL have a lower overall survival. ROC analysis of the plasma levels of sAXL, GAS6, or CA19-9 in our cohorts revealed that sAXL outperformed CA19-9 for discriminating between CP and PDAC. Using both sAXL and CA19-9 increased the diagnostic value. These results were validated in murine models, showing increased sAXL specifically in animals developing PDAC but not those with precursor lesions or acinar tumours. sAXL appears as a biomarker for early detection of PDAC and PDAC-CP discrimination that could accelerate treatment and improve its dismal prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early surgery with neuraxial anaesthesia in patients on chronic antiplatelet therapy with a proximal femur fracture, Multicentric randomised clinical trial

  • Anaya, Rafael|||0000-0003-2746-5388
  • Rodriguez Prieto, Mireia|||0000-0002-4462-534X
  • Millan, Angélica
  • Reguant, Francesca
  • Llorca Garcia, Jordi
  • Guilabert, Patricia|||0000-0001-6894-2342
  • Ruiz Pardos, Ana
  • Pantoja, Efrain|||0000-0003-4095-8988
  • Gil Sanchez, José María|||0000-0003-1422-0883
  • Moral, Victoria|||0000-0002-4061-0378
  • Merchán Galvis, Ángela María|||0000-0003-2375-5513
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
Background: Patients with proximal femur fracture on antiplatelet treatment benefit from early surgery. Our goal was to perform early surgery under neuraxial anaesthesia when indicated by the platelet function test. Methods: We conducted a multicentre randomised open-label parallel clinical trial. Patients were randomised to either early platelet function-guided surgery (experimental group) or delayed surgery (control group). Early surgery was programmed when the functional platelet count (as measured by Plateletworks) was.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease

  • Naranjo, Javier|||0000-0002-7004-6122
  • Furlano, Monica|||0000-0003-1025-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Hernández Mancera, Jonathan|||0000-0002-2267-7536
  • Pybus, Marc|||0000-0002-6195-5738
  • Ejarque, Laia
  • Cordoba, Christian|||0000-0003-4534-2760
  • Guirado, Luis|||0000-0001-5119-3912
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different available predictive tools in ADPKD with the Mayo classification (MC) identification of rapid progressors based on high total kidney volume (TKV) according to age. Methods: A total of 164 ADPKD patients were recruited retrospectively from a single centre. The performance of diverse tools to identify RP defined as being in MC categories 1C-1E was assessed. Results: A total of 118 patients were MC 1C-1E. The algorithm developed by the European Renal Association-European Dialysis and Transplant Association Working Group on Inherited Kidney Disorders/European Renal Best Practice had a low sensitivity in identifying MC 1C-1E. The sensitivity and specificity of TKV to predict RP depend on the cut-off used. A kidney length of.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Effect of Probiotics on Preterm Birth Rates in Pregnant Women After a Threatened Preterm Birth Episode (The PROPEV Trial)

  • Miserachs Sala, Marta
  • Puerto Tamayo , Linda Grace
  • Garrido-Giménez, Carmen
  • Soler, Zaida
  • Dalmau Artal, Marta
  • Casellas de Miguel, Alba
  • Carreras, Elena
  • Goya, Maria
  • del Barco Martínez, Ester
  • González Molano, Leidy Alejandra
  • VARGAS BUJÁN, MIREIA
  • Chaysavanh, Manichanh
Microbiota; Preterm birth; Probiotics, Microbiota; Parto prematuro; Probióticos, Microbiota; Part prematur; Probiòtics, Introduction: Preterm birth is the leading cause of perinatal mortality worldwide, with prevalence rates showing little reduction. Although mortality rates have decreased, morbidity rates remain concerningly high. In recent years, there has been a surge in studies examining the etiology, risk factors, and management of preterm birth. The use of vaginal probiotics in pregnant women at risk of preterm birth has garnered attention as a potential approach for improving perinatal outcomes and modulating the vaginal microbiota. However, the efficacy of this intervention remains unclear. Therefore, this study explored the impact of vaginal probiotics on perinatal outcomes and vaginal microbiota composition in pregnant women at risk of preterm birth. Materials and Methods: This was a randomized, prospective, longitudinal, double-blind, placebo-controlled, multicentric trial conducted across seven maternities in Spain from October 2017 to August 2022 in pregnant women at risk of preterm birth. Participants were randomly assigned to receive vaginal probiotics containing four lactobacilli strains or a placebo. The primary outcome was to explore a potential correlation between probiotic use among pregnant women at risk of preterm birth and the actual rate of preterm birth before 37 gestational weeks. Secondary outcomes included an evaluation of preterm birth rates, neonatal morbidity, the vaginal microbiota, and changes in the vaginal microbiota after receiving probiotics. Other secondary outcomes were identifying vaginal microbiota patterns associated with preterm birth and exploring potential therapeutic mechanisms involving probiotics. Trial registration: Clinicaltrials.gov, identifier: NCT03689166. Results: A total of 200 participants were included. Of those, birth data were obtained for 181 women. Demographics were similar between both groups. An analysis of perinatal outcomes found no significant differences in preterm birth rates, prematurity rates, gestational weeks at delivery, neonatal complications, time to birth, or latency time to delivery. Microbiota analysis showed no significant differences in vaginal microbiota changes between groups. No serious or unexpected adverse reactions were reported. Conclusions: There were no statistically significant differences for spontaneous preterm birth between pregnant women receiving probiotics and pregnant women receiving the placebo., This work was supported by the Spanish Clinical Research Network (SCReN), which is funded by the ISCIII-General Subdirectorate for Evaluation and Promotion of Research through projects PT17/0017/0030 and PT20/00078. Both projects were integrated into the 2013–2016 National Plan for Scientific and Technical Research and Innovation and co-financed by the European Regional Development Fund (ERDF), “A way of making Europe”. This work was also supported by Project FIS PI 19/00287 (Maria Goya as a principal investigator), which was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. Laboratorios Ordesa S.L funded the PROPEV study. L.-A.G.M. was supported by Instituto de Salud Carlos III/FEDER (PI20/00130).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Augustin Recio, Salvador
  • Prió, Alba
  • Sellarès-Nadal, Júlia
  • Espinosa-Pereiro, Juan
  • Burgos, Joaquin
  • Falcó, Vicenç
  • Guillen-Del-Castillo, Alfredo
  • Bañares, Juan
  • Martínez-Valle, Fernando
  • Kirkegaard, Cristina
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Acute respiratory distress syndrome; COVID-19; Interleukin-6, Síndrome de dificultat respiratòria aguda; COVID-19; Interleucina-6, Síndrome de dificultad respiratoria aguda; COVID-19; Interleucina-6, Background The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels > 40 pg/mL. Methods Patients were randomized 1:1 to receive standard of care (SOC) or SOC plus one dose of tocilizumab. The primary outcome was death or need for invasive mechanical ventilation (IMV) within 28 days after randomization. Secondary outcomes included ICU admission, days on IMV and hospital stay. A meta-analysis of clinical trials to evaluate the effect of tocilizumab on mortality and need of IMV in patients with COVID-19 pneumonia was performed. Results Sixty-two patients were included: 30 in the SOC arm and 32 in the standard-treatment plus tocilizumab arm. The primary outcome occurred in 12.9% in the tocilizumab arm and 32.3% in the SOC arm(p = 0.068). There was a trend towards fewer days on IMV (7.5 vs 19.5 days, p = 0.073) and a shorter hospital stay (4 vs 8 days, p = 0.134) in the tocilizumab group. No serious adverse events were reported. The meta-analysis revealed a RR for death or IMV of 0.83 (95% CI: 0.77–0.89) in patients receiving tocilizumab, compared to patients receiving SOC. Conclusion Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19., Open Access Funding provided by Universitat Autonoma de Barcelona. This study received support of “Plataforma ISCIII de Soporte para la Investigación Clínica—SCReN (Spanish Clinical Research Network)” which is funded by ISCIII through the project sPT17/0017/0030 and PT20/00078, which are both integrated in the “Plan Estatal de I + D + I 2013–2016 y 2017–2020” and co-funded by the “ Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa””. ASM was supported by the Instituto de Salud Carlos III (Juan Rodés postdoctoral fellowship grant number JR18/00022) during the study period. JSN and JEP are supported by the Instituto de Salud Carlos III (Rio Hortega predoctoral grant numbers CM22/00262 and CM22/00246).